Securities Daily Online News: On February 26, Baiao Tai responded to investor questions on the interactive platform, stating that the sales of Bevacizumab in Europe and the United States are led by partners; the commercialization of Tocilizumab and Ustekinumab in Europe is also actively being prepared. The company will continue to work closely with partners to accelerate the expansion into overseas markets.
(Editor: Wang Xueer)
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Baotai: The European and American sales of Bevacizumab are led and promoted by the partner
Securities Daily Online News: On February 26, Baiao Tai responded to investor questions on the interactive platform, stating that the sales of Bevacizumab in Europe and the United States are led by partners; the commercialization of Tocilizumab and Ustekinumab in Europe is also actively being prepared. The company will continue to work closely with partners to accelerate the expansion into overseas markets.
(Editor: Wang Xueer)